Recursion CEO Chris Gibson talks integrating AI into drug development process
21:23
Foundation Models in Drug Discovery: Recursion VP of AI Stephen MacKinnon | Ray Summit 2024
16:18
An AI Drug Discovery Stock We Like
4:35
Jim Cramer on what 2025 could hold for Nvidia
16:49
Download Day 2023 — State of Drug Discovery & State of Recursion by Chris Gibson, Co-founder & CEO
4:49
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner
4:00
'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson
8:54
I think Nvidia sees us as a leader of this new space of AI-driven biotech: Recursion CEO
6:17